Johnson&Johnson sales bolstered again by devices and diagnostics as Cypher and new hips and knees forge ahead
This article was originally published in Clinica
Continuing the trend of the past several quarters, Johnson & Johnson's medical device and diagnostics businesses helped prop up sales growth as US pharmaceutical revenues suffered from increasing generic drug competition.
You may also be interested in...
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
No device-related warning letters were released by the US FDA the week of 19 February.
Complex generics and value added medicines share common challenges on harmonization of regulation, lack of incentives and clarity of guidelines, heard delegates to Medicines for Europe’s Regulatory & Scientific Affairs conference.